DNA methylation-driven gene-based drug response prediction model for liver cancer: The critical role of GLS
The three-gene MDG-based prognostic model effectively predicts survival outcomes in LIHC patients. Moreover, the methylation status of GLS serves as a biomarker for assessing immune microenvironment characteristics, responsiveness to immunotherapy, and chemotherapy sensitivity, highlighting its potential as a therapeutic target in liver cancer.
Authors
- Chenyu Sun (ORCID: https://orcid.org/0000-0003-3812-3164)
- Xiaozhou Wang (ORCID: https://orcid.org/0000-0003-4351-6499)
- Yu Xi (ORCID: https://orcid.org/0000-0001-6385-8862)
- Lijie He (ORCID: https://orcid.org/0000-0002-0586-5877)
- Wei Wu (ORCID: https://orcid.org/0000-0001-6159-3346)
- Yujia Han (ORCID: https://orcid.org/0009-0003-9473-4530)
- Yi Ma (ORCID: https://orcid.org/0000-0003-3514-8614)
- Jing Zhang (ORCID: https://orcid.org/0000-0002-9957-3372)
- Shuang Zheng
Institutions
- Liaoning Provincial People's Hospital (CN)
- The Sixth People's Hospital of Shenyang (CN)
- China Medical University (CN)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-12-05
- DOI
- https://doi.org/10.1371/journal.pone.0338091
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00